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Maternal and umbilical homocysteine in preeclampsia
Abstract
Background and purpose: Were to assess the association between homo-
cysteine levels and development of preeclampsia, to determine homocysteine 
levels in fetal circulation, to differentiate homocysteine levels in mild and 
severe preeclampsia and to compare homocysteine levels in pregnant women 
with preeclampsia with homocysteine levels measured in the same group of 
women six months after delivery.
Material and methods: The study included 55 pregnant women with 
mild or severe preeclampsia (hypertensia with proteinuria), while control 
group of 50 healthy pregnant women. Maternal and umbilical blood ho-
mocysteine levels were determined by the fluorescence polarization immu-
noassay. Shapiro-Wilks, Mann-Whitney and Wilcoxon statistical tests per-
formed for statistical analysis.
Results: In women with preeclampsia, the mean homocysteine level was 
by 0.744 µmol/L higher than in control women; with mild preeclampsia, 
the level was by 2.752 µmol/L lower as compared to the women with severe 
preeclampsia (p < 0.0001). In women with preeclampsia, the mean um-
bilical blood homocysteine level was by 0.268 µmol/L lower than the respec-
tive level measured in control group (p < 0.0001). In women with pre-
eclampsia, the mean homocysteine level was by 0.878 µmol/L lower in the 
same group of women six months after delivery (p < 0.0001).
Conclusion: Homocysteine are lower in preeclamptic women six months 
after delivery. The neonates born to mothers with preeclampsia are not at a 
higher exposure to homocysteine.
 
IntroductIon
Since the 1990s, homocysteine has been associated with disorders of the fetomaternal unit (1). Studies on recurrent abortions also found 
clear association between elevated homocysteine levels and the risk of 
abortion (2,3). Later on, Vollset et al. (4) found the levels of homocys-
teine to be associated with the prevalence of preeclampsia, preterm de-
livery, low birth weight, intrauterine growth restriction (IUGR), still-
birth, congenital malformations and abruptio placentae. The association 
of mild hyperhomocysteinemia with cardiovascular disease and related 
mortality was demonstrated in a number of studies (5-11).
Hyperhomocysteinemia alters vascular morphology, stimulates in-
flammation, activates endothelium and blood clotting cascade, and 
inhibits fibrinolysis. Hyperhomocysteinemia results in the loss of endo-
thelial antithrombin function and induction of a procoagulant setting 
(9,12). The pathogenetic action of homocysteine also includes interfer-
ence with the nitric oxide (NO) system (homocysteine reduces NO 
bioavailability by interfering with its synthesis), activation of transcrip-
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tion factors stimulating gene expression (activation of 
sterol-regulatory element-binding protein (SREBP) and 
protein kinase C (PKC), lipid biosynthesis), chemotaxis 
and leukocyte adhesion (sICAM-1, VCAM-1, interleu-
kin-8, von Willebrand’s factor) (13,14).
The aims of the study were to assess the association 
between elevated homocysteine levels and development 
of preeclampsia; to determine homocysteine levels in fetal 
circulation; to differentiate homocysteine levels in mild 
and severe preeclampsia; and to compare homocysteine 
levels in pregnant women with preeclampsia with homo-
cysteine levels measured in the same group of women six 
months after delivery.
methods
The study included 55 pregnant women with verified 
milde preeclampsia (blood pressure measured on two oc-
casions at least 4 h apart ≥140/90 mm Hg after 20th week 
of gestation, and positive proteinuria) and severe pre-
eclampsia (blood pressure ≥160/110 mm Hg, proteinuria 
≥++). Control group consisted of 50 healthy pregnant 
women, as approved by the Ethics Committee of the 
Osijek University Hospital. All pregnant women are tak-
ing folate supplements and vitamins, including B6 and 
B12 during pregnancy and puerperium (Elevit®, Bayer, 
Germany). In both preeclampsia and control group, ho-
mocysteine levels were measured after at least 12-h fast-
ing. Umbilical blood homocysteine levels were deter-
mined in the same groups of women after delivery, during 
third stage. In the group of women with preeclampsia, 
blood homocysteine was also determined six months after 
delivery. Homocysteine levels were determined by the 
FPIA (fluorescence polarization immunoassay) technol-
ogy on an AxSYM device (Abbott Laboratories) using 
reagents of the same manufacturer (Testkit Code No. 
5F51-20). According to Khong and Hague (15), hyperho-
mocysteinemia is present in pregnant women when the 
level of homocysteine exceeds 10.9 μmol/L.
On statistical analysis, the basic characteristics of the 
sample consisting of women with preeclampsia and con-
trol women were determined first. Because of the rela-
tively small number of study subjects, the Shapiro-Wilks 
test, t-test for dependent variables and Levene’s test were 
used. When the Shapiro-Wilks test failed to confirm the 
hypothesis of normal distribution, Mann-Whitney and 
Wilcoxon tests were employed. Differences confirmed at 
the level of p<0.05 were considered to be statistically sig-
nificant. Data were prepared by use of the Microsoft Ex-
cel calculator, while the SPSS and Statistica packages were 
used on data processing. Box and Whisker Plot diagrams 
were done by the Statistica application because the reasons 
stated statistical data processing.
results
Age and parity in two groups were no statistic signifi-
cantly, but gestational age in preeclamptic women are 
shortly 35,5 vs 39,1 weeks (p< 0,0001) because high num-
ber induced and preterm delivery.
In women with preeclampsia, the mean homocysteine 
level was 6.758 μmol/L. According to median, the mean 
level of homocysteine was ≤6.4 μmol/L and ≥6.4 μmol/L 
in 50% of women with preeclampsia each. In control 
group, the mean homocysteine level was 6.014 μmol/L. 
According to median, the mean homocysteine level was 
≤5.8 μmol/L and ≥5.8 μmol/L in 50% of control women 
each. The lowest and highest homocysteine level was 2.6 
μmol/L and 9.8 μmol/L, respectively, yielding a range of 
variation of 7.2 μmol/L (Figure 1). In preeclampsia group, 
the mean homocysteine level was greater by 0.744 μmol/L 
and the median calculated for these women by 0.6 μmol/L 
than the respective values recorded in control group. The 
Mann-Whitney test indicated nonexistence of statisti-
cally significant differences in homocysteine levels be-
tween the group of women with preeclampsia and control 
group (Z=-1.733, p=0.083). In women with mild pre-
eclampsia, the mean homocysteine level was 6.008 
μmol/L. The lowest and highest homocysteine level was 
3.9 μmol/L and 8.6 μmol/L, respectively, yielding a range 
of variation of 4.7 μmol/L. In women with severe pre-
eclampsia the mean homocysteine level was 8.760 
μmol/L. According to median, the mean homocysteine 
level was ≤8.6 μmol/L and ≥8.6 μmol/L in 50% of wom-
en with severe preeclampsia each. In women with mild 
preeclampsia, the mean homocysteine level was by 2.752 
μmol/L lower than the mean homocysteine level recorded 
in women with severe preeclampsia, whereas the median 
Figure 1. Box and Whisker Plot diagram of variables defined as 
homocysteine level in women with preeclampsia and control 
women.
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calculated for women with mild preeclampsia was lower 
by 2.8 μmol/L (Figure 2). Mann-Whitney test yielded a 
statistically significant difference in homocysteine level 
between pregnant women with mild preeclampsia and 
those with severe preeclampsia (Z=-4.199, p < 0.0001).
In the neonates born to mothers with preeclampsia and 
those born to mothers from control group, the mean level 
of umbilical homocysteine was 5.044 μmol/L and 5.312 
μmol/L, respectively (Figure 3). In women with preeclamp-
sia, the mean homocysteine level was by 0.268 μmol/L 
lower than the respective level measured in control women, 
while the median calculated for women with preeclampsia 
was lower by 0.2 μmol/L. Spearman’s rank correlation coef-
ficient between maternal and umbilical homocysteine 
yielded a moderately positive statistically significant correla-
tion (?? =0.670, p < 0.0001). In women with preeclampsia, 
the mean homocysteine level was 6.758 μmol/L. According 
to median, the mean homocysteine level was ≤6.4 μmol/L 
and ≥6.4 μmol/L in 50% of women with preeclampsia 
each. The mean homocysteine level measured in women 
with preeclampsia six months after delivery was 7.636 
μmol/L (Figure 4). In pregnant women with preeclampsia, 
the mean homocysteine level was lower by 0.878 μmol/L 
and the median calculated for these women by 1.3 μmol/L 
than the respective figures recorded six months after deliv-
ery. Wilcoxon test yielded a statistically significant differ-
ence in homocysteine level in preeclampsia women before 
and after delivery (Z=-3.604, p < 0.0001).
dIscussIon
The pattern of the amino acid homocysteine behavior 
in preeclampsia has been investigated in many studies, 
Figure 2. Box and Whisker Plot diagram of variables defined as 
homocysteine level in women with mild preeclampsia and severe 
preeclampsia.
Figure 3. Box and Whisker Plot diagram of variables defined as 
umbilical homocysteine level in women with preeclampsia and 
control women.
Figure 4. Box and Whisker Plot diagram of variables defined as 
homocysteine level in women with preeclampsia before and after 
delivery.
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with sharply opposed results. In the study by Powers et al. 
(16), the mean homocysteine levels were significantly el-
evated (p<0.04) in women with preeclampsia as compared 
with control group (9.7 μmol/L vs. 7.0 μmol/L). Similar 
results (6.7 μmol/L vs. 3.8 μmol/L; p<0.01) have also been 
reported by Laviouri et al. (17). These two studies were of 
a similar design, conducted in a sample of 50 primiparae; 
however, in the former study, blood samples were ob-
tained before delivery after 6-hour fasting, whereas in the 
latter blood samples were collected during third trimester 
after at least 12-hour fasting. Therefore, differences in the 
mean homocysteine levels could be ascribed to variation 
in sampling time. Rajkovic et al. (18) conducted a study 
on African women and found the risk of developing pre-
eclampsia to be 4.57-fold greater (OR=4.57.2; 95%CI: 
2.11-9.88) in women with higher homocysteine levels, 
whereas Sorensen et al. (19) demonstrated the respective 
risk to be 3.2-fold greater (OR=3.2; 95%CI: 1.11-9.2). The 
latter two studies showed the risk to increase significant-
ly in primiparae in comparison with multiparae with 
comparable homocysteine levels. The risk was 12.9-fold 
greater in African primiparae (OR=12.9; 95%CI: 5.28-
31.53) and 9.7-fold greater in American primiparae 
(OR=9.7; 95%CI: 2.1-14). Both studies were adjusted for 
various confounding factors by multivariate analysis. 
Variations between the studies could be attributed to dif-
ferences in the number of study subjects (more than 
double in the former study) and the time of blood sam-
pling because it was performed after delivery in African 
women and in second trimester in American women. Our 
results showed the mean homocysteine level (6.758±2.062 
μmol/L) and median (6.400 μmol/L) calculated for wom-
en with preeclampsia to exceed the respective values re-
corded in the control group of women free from pre-
eclampsia (6.014±1.539 μmol/L and 5.800 μmol/L); 
however, the between-group difference in homocysteine 
levels did not reach statistical significance. Makedos et al. 
(20) compared homocysteine levels in a group of pregnant 
women with preeclampsia and control group free from 
preeclampsia and found the mean homocysteine level to 
be significantly increased in the former (11.11 μmol/L vs. 
6.40 μmol/L, p<0.001). There was no between-group dif-
ference in the folic acid and vitamin B12 levels. The group 
of women with preeclampsia was associated with a high-
er rate of cesarean section, IUGR (50%) and abruptio 
placentae (20).
Malinow et al. (21) investigated the relationship of ho-
mocysteine levels in maternal venous blood, umbilical 
vein and umbilical artery and found a decreasing concen-
tration gradient with 1 μmol/L difference for each of the 
samples tested. The mean homocysteine level in maternal 
plasma was 5.43±1.40 μmol/L, by approximately 1 
μmol/L greater than the mean homocysteine level in um-
bilical vein (4.49±1.78 μmol/L). These authors also report 
on positive correlation between umbilical homocysteine 
(umbilical artery and umbilical vein) and maternal plasma 
homocysteine. Based on these results, they suggest the 
possibility of transplacental transfer of maternal homo-
cysteine to the umbilical vein, thus being incorporated in 
the fetal metabolic cycle. These authors also found nega-
tive correlation of maternal homocysteine with gestation-
al age and neonatal birth weight, and explain it by fetal 
utilization of homocysteine proportionate to fetal weight 
and gestational age (21). These results explain the homo-
cysteine decline in normal pregnancy (21,22). Similar 
results were also recorded in the present study; however, 
in the group of pregnant women with preeclampsia, the 
mean homocysteine level was lower than the respective 
level measured in the same group of women six months 
after delivery, the difference being statistically significant.
In contrast to the studies mentioned above but similar 
to our results, Mignini et al. (23) published results of a 
systematic review that included 25 studies, 8 and 17 of 
which measured serum homocysteine levels before and 
after the onset of preeclampsia, respectively. In many of 
these studies, differences in the mean homocysteine levels 
according to gestational age were recorded both in normal 
pregnancy and in women with preeclampsia, especially 
those with severe preeclampsia (mean difference: 1.42 
μmol/L, 95%CI: 0.53-2.30), unlike women with mild 
preeclampsia (mean difference: 0.60 μmol/L, 95%CI: 
0.30-0.89). These biological gradients were not statisti-
cally significant.
The investigators analyzed the possible etiologic factors 
of hyperhomocysteinemia (folate and vitamin B12 levels 
and genetic polymorphisms) and found no association 
with hyperhomocysteinemia. Then they assessed the pos-
sible effect of hyperhomocysteinemia on the development 
of preeclampsia via oxidative stress and endothelial dys-
function, as we also postulated in our study, and found 
the studies reviewed to report divergent input and poor 
correlation of the factors assessed, i.e. absence of biologi-
cal plausibility; therefore, they consider that the associa-
tion of hyperhomocysteinemia and preeclampsia cannot 
be explained by the current literature data (23). In con-
trast to the study by Mignini et al. (23), a more recent 
report by Acilmis et al. (24) offers an explanation of the 
obscurities related to hyperhomocysteinemia and preg-
nancy by differentiating severe and mild preeclampsia. 
They monitored the levels of homocysteine, folic acid and 
vitamin B12 in three groups of pregnant women, i.e. se-
vere preeclampsia, mild preeclampsia and normal preg-
nancy, and found statistically significantly higher homo-
cysteine levels in maternal and fetal (umbilical) blood in 
the group of women with severe preeclampsia as com-
pared with the groups of women with normal pregnancy 
and those with mild preeclampsia. There was no statisti-
cally significant difference in the levels of maternal and 
fetal (umbilical) homocysteine between the groups of 
women with normal pregnancy and those with mild pre-
eclampsia. There was no statistically significant between-
group difference in folic acid and vitamin B12 levels in 
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maternal and fetal (umbilical) samples either. The authors 
conclude that the levels of homocysteine are significantly 
higher in the group of women with severe preeclampsia 
as compared with the groups of women with mild pre-
eclampsia and those with normal pregnancy, suggesting 
that the increased homocysteine levels may be associated 
with the severity of preeclampsia. They also consider that 
elevated homocysteine levels do not appear to be accom-
panied by folic acid and vitamin B12 deficiency (24). A 
similar homocysteine pattern was also observed in our 
study. Subdivision of our group of pregnant women ac-
cording to the severity of preeclampsia based on the cri-
teria of blood pressure ≥160/110 mm Hg and proteinuria 
≥++ (10 mg/dL) yielded two subgroups of women (15 with 
severe preeclampsia and 40 with mild preeclampsia) that 
differed significantly according to the mean homocyste-
ine levels. In the subgroup of women with severe pre-
eclampsia, the mean homocysteine level (8.760±2.156 
μmol/L) and median (8.6 μmol/L) exceeded the respec-
tive values recorded in women with mild preeclampsia 
(6.008±1.449 μmol/L and 5.8 μmol/L, respectively). 
White et al. proven of differences in homocysteine levels 
between the subgroups were also statistically significant. 
A history of hypertension in pregnancy, when compared 
with normotensive pregnancy, was associated with a 4.5% 
higher serum homocysteine level and 1.60-fold increased 
odds of having an elevated after adjusting for potentially 
confounding covariates. Aa history of normotensive preg-
nancy, as compared with nulliparity, was associated with 
a 6.1% lower serum homocysteine level and a 0.49-fold 
reduced odds of elevated homocysteine levels (25). Other 
recently investigations they found significantly higher 
values umbilical homocysteine in womens with severe 
preeclampsia, but without only indicate some degree of 
in-utero fetal cardiac cell damage (26).
Our results suggested that there was no difference in 
homocysteine levels between normal pregnancies and 
pregnancies complicated by preeclampsia, but homocys-
teine levels in women with preeclampsia were statistically 
significantly lower than homocysteine levels measured in 
the same group of women six months after delivery. In 
women with severe preeclampsia, homocysteine levels 
exceeded those in women with mild preeclampsia. How-
ever, our study results yielded no statistical evidence for 
the infants born to mothers with preeclampsia to be at a 
higher exposure to homocysteine than those born to 
mothers with normal pregnancy.
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